SWOG clinical trial number
S1929

Phase II Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (SCLC)

100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Abbreviated Title
Phase II Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (SCLC)
Status Notes
S1929 will open to accrual June 15, 2020, effective 12:00 pm PST.

Effective August 15, 2022, at 3:45 a.m. Pacific Time, S1929 Step 1 Screening Registration will be permanently closed to accrual, as it has met the protocol specified accrual goal.
Activated
06/15/2020
Closed
12/15/2022

Research committees

Lung Cancer

Treatment

Atezolizumab Talazoparib

Other Clinical Trials

S2414
SWOG Clinical Trial Number
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
1% Accrual
Accrual
1%
Open
Phase
CTSU/NRG-LU007
SWOG Clinical Trial Number